10:01 AM EDT, 07/30/2025 (MT Newswires) -- AbbVie ( ABBV ) said Wednesday that one of two phase 3 pivotal studies of upadacitinib in adult and adolescent patients with severe alopecia areata met its primary endpoint of more scalp hair coverage and key secondary endpoints of improvements in eyebrows and eyelashes.

The company said 44.6% and 54.3% of the patients treated with upadacitinib 15 mg and 30 mg respectively achieved 80% or more scalp hair coverage at week 24, compared with 3.4% of patients who received placebo.

The safety profile of both doses was generally consistent with that in approved indications and no new safety indications were observed, the company said.

AbbVie ( ABBV ) said it expects to release the results of the phase 3 trial's parallel replicate study in Q3.

Price: 190.95, Change: -0.29, Percent Change: -0.15